Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial

Marcus A. Bachhuber, Denis Nash, William N. Southern, Moonseong Heo, Matthew Alan Berger, Mark Schepis, Chinazo O. Cunningham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

INTRODUCTION: As opioid analgesic consumption has grown, so have opioid use disorder and opioid-related overdoses. Reducing the quantity of opioid analgesics prescribed for acute non-cancer pain can potentially reduce risks to the individual receiving the prescription and to others who might unintentionally or intentionally consume any leftover tablets. Reducing the default dispense quantity for new opioid analgesic prescriptions in the electronic health record (EHR) is a promising intervention to reduce prescribing. METHODS AND ANALYSIS: This study is a prospective cluster randomised controlled trial with two parallel arms. Primary care sites (n=32) and emergency departments (n=4) will be randomised in matched pairs to either a modification of the EHR so that new opioid analgesic prescriptions default to a dispense quantity of 10 tablets (intervention) or to no EHR change (control). The dispense quantity will remain fully modifiable by providers in both arms. From 6 months preintervention to 18 months postintervention, patient-level data will be analysed (ie, the patient is the unit of inference). Patient eligibility criteria are: (A) received a new opioid analgesic prescription, defined as no other opioid analgesic prescription in the prior 6 months; (B) age ≥18 years; and (C) no cancer diagnosis within 1 year prior to the new opioid analgesic prescription. The primary outcome will be the quantity of opioid analgesics prescribed in the initial prescription. Secondary outcomes will include opioid analgesic reorders and health service utilisation within 30 days after the initial prescription. Outcomes will be compared between study arms using a difference-in-differences analysis. ETHICS AND DISSEMINATION: This study has been approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board with a waiver of informed consent (2016-6036) and is registered on ClinicalTrials.gov (NCT03003832, 6 December 2016). Findings will be disseminated through publication, conferences and meetings with health system leaders. TRIAL REGISTRATION NUMBER: NCT03003832; Pre-results.

Original languageEnglish (US)
Pages (from-to)e019559
JournalBMJ Open
Volume8
Issue number4
DOIs
StatePublished - Apr 20 2018

Fingerprint

Opioid Analgesics
Prescriptions
Randomized Controlled Trials
Electronic Health Records
Tablets
Opioid-Related Disorders
Research Ethics Committees
Informed Consent
Health Services
Publications
Hospital Emergency Service
Primary Health Care
Medicine
Pain
Health

Keywords

  • acute pain
  • default
  • electronic health record
  • opioid analgesics
  • pain management

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reducing the default dispense quantity for new opioid analgesic prescriptions : study protocol for a cluster randomised controlled trial. / Bachhuber, Marcus A.; Nash, Denis; Southern, William N.; Heo, Moonseong; Berger, Matthew Alan; Schepis, Mark; Cunningham, Chinazo O.

In: BMJ Open, Vol. 8, No. 4, 20.04.2018, p. e019559.

Research output: Contribution to journalArticle

@article{8a2cc40e65e941a38fd9bfa2d234ab71,
title = "Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial",
abstract = "INTRODUCTION: As opioid analgesic consumption has grown, so have opioid use disorder and opioid-related overdoses. Reducing the quantity of opioid analgesics prescribed for acute non-cancer pain can potentially reduce risks to the individual receiving the prescription and to others who might unintentionally or intentionally consume any leftover tablets. Reducing the default dispense quantity for new opioid analgesic prescriptions in the electronic health record (EHR) is a promising intervention to reduce prescribing. METHODS AND ANALYSIS: This study is a prospective cluster randomised controlled trial with two parallel arms. Primary care sites (n=32) and emergency departments (n=4) will be randomised in matched pairs to either a modification of the EHR so that new opioid analgesic prescriptions default to a dispense quantity of 10 tablets (intervention) or to no EHR change (control). The dispense quantity will remain fully modifiable by providers in both arms. From 6 months preintervention to 18 months postintervention, patient-level data will be analysed (ie, the patient is the unit of inference). Patient eligibility criteria are: (A) received a new opioid analgesic prescription, defined as no other opioid analgesic prescription in the prior 6 months; (B) age ≥18 years; and (C) no cancer diagnosis within 1 year prior to the new opioid analgesic prescription. The primary outcome will be the quantity of opioid analgesics prescribed in the initial prescription. Secondary outcomes will include opioid analgesic reorders and health service utilisation within 30 days after the initial prescription. Outcomes will be compared between study arms using a difference-in-differences analysis. ETHICS AND DISSEMINATION: This study has been approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board with a waiver of informed consent (2016-6036) and is registered on ClinicalTrials.gov (NCT03003832, 6 December 2016). Findings will be disseminated through publication, conferences and meetings with health system leaders. TRIAL REGISTRATION NUMBER: NCT03003832; Pre-results.",
keywords = "acute pain, default, electronic health record, opioid analgesics, pain management",
author = "Bachhuber, {Marcus A.} and Denis Nash and Southern, {William N.} and Moonseong Heo and Berger, {Matthew Alan} and Mark Schepis and Cunningham, {Chinazo O.}",
year = "2018",
month = "4",
day = "20",
doi = "10.1136/bmjopen-2017-019559",
language = "English (US)",
volume = "8",
pages = "e019559",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Reducing the default dispense quantity for new opioid analgesic prescriptions

T2 - study protocol for a cluster randomised controlled trial

AU - Bachhuber, Marcus A.

AU - Nash, Denis

AU - Southern, William N.

AU - Heo, Moonseong

AU - Berger, Matthew Alan

AU - Schepis, Mark

AU - Cunningham, Chinazo O.

PY - 2018/4/20

Y1 - 2018/4/20

N2 - INTRODUCTION: As opioid analgesic consumption has grown, so have opioid use disorder and opioid-related overdoses. Reducing the quantity of opioid analgesics prescribed for acute non-cancer pain can potentially reduce risks to the individual receiving the prescription and to others who might unintentionally or intentionally consume any leftover tablets. Reducing the default dispense quantity for new opioid analgesic prescriptions in the electronic health record (EHR) is a promising intervention to reduce prescribing. METHODS AND ANALYSIS: This study is a prospective cluster randomised controlled trial with two parallel arms. Primary care sites (n=32) and emergency departments (n=4) will be randomised in matched pairs to either a modification of the EHR so that new opioid analgesic prescriptions default to a dispense quantity of 10 tablets (intervention) or to no EHR change (control). The dispense quantity will remain fully modifiable by providers in both arms. From 6 months preintervention to 18 months postintervention, patient-level data will be analysed (ie, the patient is the unit of inference). Patient eligibility criteria are: (A) received a new opioid analgesic prescription, defined as no other opioid analgesic prescription in the prior 6 months; (B) age ≥18 years; and (C) no cancer diagnosis within 1 year prior to the new opioid analgesic prescription. The primary outcome will be the quantity of opioid analgesics prescribed in the initial prescription. Secondary outcomes will include opioid analgesic reorders and health service utilisation within 30 days after the initial prescription. Outcomes will be compared between study arms using a difference-in-differences analysis. ETHICS AND DISSEMINATION: This study has been approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board with a waiver of informed consent (2016-6036) and is registered on ClinicalTrials.gov (NCT03003832, 6 December 2016). Findings will be disseminated through publication, conferences and meetings with health system leaders. TRIAL REGISTRATION NUMBER: NCT03003832; Pre-results.

AB - INTRODUCTION: As opioid analgesic consumption has grown, so have opioid use disorder and opioid-related overdoses. Reducing the quantity of opioid analgesics prescribed for acute non-cancer pain can potentially reduce risks to the individual receiving the prescription and to others who might unintentionally or intentionally consume any leftover tablets. Reducing the default dispense quantity for new opioid analgesic prescriptions in the electronic health record (EHR) is a promising intervention to reduce prescribing. METHODS AND ANALYSIS: This study is a prospective cluster randomised controlled trial with two parallel arms. Primary care sites (n=32) and emergency departments (n=4) will be randomised in matched pairs to either a modification of the EHR so that new opioid analgesic prescriptions default to a dispense quantity of 10 tablets (intervention) or to no EHR change (control). The dispense quantity will remain fully modifiable by providers in both arms. From 6 months preintervention to 18 months postintervention, patient-level data will be analysed (ie, the patient is the unit of inference). Patient eligibility criteria are: (A) received a new opioid analgesic prescription, defined as no other opioid analgesic prescription in the prior 6 months; (B) age ≥18 years; and (C) no cancer diagnosis within 1 year prior to the new opioid analgesic prescription. The primary outcome will be the quantity of opioid analgesics prescribed in the initial prescription. Secondary outcomes will include opioid analgesic reorders and health service utilisation within 30 days after the initial prescription. Outcomes will be compared between study arms using a difference-in-differences analysis. ETHICS AND DISSEMINATION: This study has been approved by the Montefiore Medical Center/Albert Einstein College of Medicine Institutional Review Board with a waiver of informed consent (2016-6036) and is registered on ClinicalTrials.gov (NCT03003832, 6 December 2016). Findings will be disseminated through publication, conferences and meetings with health system leaders. TRIAL REGISTRATION NUMBER: NCT03003832; Pre-results.

KW - acute pain

KW - default

KW - electronic health record

KW - opioid analgesics

KW - pain management

UR - http://www.scopus.com/inward/record.url?scp=85056615256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056615256&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2017-019559

DO - 10.1136/bmjopen-2017-019559

M3 - Article

C2 - 29678969

AN - SCOPUS:85056615256

VL - 8

SP - e019559

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 4

ER -